Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET

NeuroImage

Volumn 88, Issue , 2014, Pages 252-262

  Baldinger, Pia ^a   Kranz, Georg S ^a   Haeusler, Daniela ^a   Savli, Markus ^a   Spies, Marie ^a   Philippe, Cecile ^a   Hahn, Andreas ^a   Höflich, Anna ^a   Wadsak, Wolfgang ^a   Mitterhauser, Markus ^a   Lanzenberger, Rupert ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressant; Occupancy; PET; Serotonin transporter; Subgenual cingulate cortex

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN TRANSPORTER;

ADOLESCENT; ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN CORTEX; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAPHE NUCLEUS; SUBCORTEX; YOUNG ADULT;

ANTIDEPRESSANT; OCCUPANCY; PET; SEROTONIN TRANSPORTER; SUBGENUAL CINGULATE CORTEX;

ADULT; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84896723332     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.10.002     Document Type: Article

References (51)

1. Benmansour S., Cecchi M., Morilak D.A., Gerhardt G.A., Javors M.A., Gould G.G., Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J. Neurosci. 1999, 19:10494-10501.
2. Benmansour S., Owens W.A., Cecchi M., Morilak D.A., Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 2002, 22:6766-6772.
3. Best J., Nijhout H.F., Reed M. Bursts and the efficacy of selective serotonin reuptake inhibitors. Pharmacopsychiatry 2011, 44(Suppl. 1):S76-S83.
4. Blier P., de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 1999, 21:91S-98S.
5. El Mansari M., Sanchez C., Chouvet G., Renaud B., Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005, 30:1269-1277.
6. Fink M., Wadsak W., Savli M., Stein P., Moser U., Hahn A., Mien L.-K., Kletter K., Mitterhauser M., Kasper S., Lanzenberger R. Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. NeuroImage 2009, 45:598-605.
7. Garris P.A., Wightman R.M. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 1994, 14:442-450.
8. Gill J.S., Beevers D.G., Zezulka A.V., Davies P. Relation between initial blood pressure and its fall with treatment. Lancet 1985, 325:567-569.
9. Grunder G., Landvogt C., Vernaleken I., Buchholz H.G., Ondracek J., Siessmeier T., Hartter S., Schreckenberger M., Stoeter P., Hiemke C., Rosch F., Wong D.F., Bartenstein P. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006, 31:1027-1035.
10. Grunder G., Fellows C., Janouschek H., Veselinovic T., Boy C., Brocheler A., Kirschbaum K.M., Hellmann S., Spreckelmeyer K.M., Hiemke C., Rosch F., Schaefer W.M., Vernaleken I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am. J. Psychiatry 2008, 165:988-995.
11. Haeusler D., Mien L.K., Nics L., Ungersboeck J., Philippe C., Lanzenberger R.R., Kletter K., Dudczak R., Mitterhauser M., Wadsak W. Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. Appl. Radiat. Isot. 2009, 67:1654-1660.
12. Hinz R., Selvaraj S., Murthy N.V., Bhagwagar Z., Taylor M., Cowen P.J., Grasby P.M. Effects of citalopram infusion on the serotonin transporter binding of [11C]DASB in healthy controls. J. Cereb. Blood Flow Metab. 2008, 28:1478-1490.
13. Hoflich A., Baldinger P., Savli M., Lanzenberger R., Kasper S. Imaging treatment effects in depression. Rev. Neurosci. 2012, 23:227-252.
14. Ichise M., Liow J.S., Lu J.Q., Takano A., Model K., Toyama H., Suhara T., Suzuki K., Innis R.B., Carson R.E. Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J. Cereb. Blood Flow Metab. 2003, 23:1096-1112.
15. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.-C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
16. Kasper S., Sacher J., Klein N., Mossaheb N., Attarbaschi-Steiner T., Lanzenberger R., Spindelegger C., Asenbaum S., Holik A., Dudczak R. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int. Clin. Psychopharmacol. 2009, 24:119-125.
17. Kegeles L.S., Slifstein M., Frankle W.G., Xu X., Hackett E., Bae S.A., Gonzales R., Kim J.H., Alvarez B., Gil R., Laruelle M., Abi-Dargham A. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008, 33:3111-3125.
18. Kingback M., Carlsson B., Ahlner J., Bengtsson F., Kugelberg F.C. Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats. Chirality 2011, 23:172-177.
19. Kranz G.S., Kasper S., Lanzenberger R. Reward and the serotonergic system. Neuroscience 2010, 166:1023-1035.
20. Kranz G.S., Hahn A., Savli M., Lanzenberger R. Challenges in the differentiation of midbrain raphe nuclei in neuroimaging research. Proc. Natl. Acad. Sci. 2012, 109:E2000.
21. Kugelberg F.C., Apelqvist G., Carlsson B., Ahlner J., Bengtsson F. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br. J. Pharmacol. 2001, 132:1683-1690.
22. Kugelberg F.C., Carlsson B., Ahlner J., Bengtsson F. Stereoselective single-dose kinetics of citalopram and its metabolites in rats. Chirality 2003, 15:622-629.
23. Kugelberg F.C., Druid H., Carlsson B., Ahlner J., Bengtsson F. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats. J. Anal. Toxicol. 2004, 28:631-637.
24. Lanzenberger R., Kranz G.S., Haeusler D., Akimova E., Savli M., Hahn A., Mitterhauser M., Spindelegger C., Philippe C., Fink M., Wadsak W., Karanikas G., Kasper S. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage 2012, 63:874-881.
25. Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol. Imaging Biol. 2003, 5:363-375.
26. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20:612-627.
27. Lundberg J., Tiger M., Landén M., Halldin C., Farde L. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 2012, 15:1167-1172.
28. Mayberg H.S. Targeted electrode-based modulation of neural circuits for depression. J. Clin. Invest. 2009, 119:717-725.
29. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 2007, 32:86-102.
30. Meyer J.H., Wilson A.A., Ginovart N., Goulding V., Hussey D., Hood K., Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am. J. Psychiatry 2001, 158:1843-1849.
31. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z., Ginovart N., Spencer E.P., Cheok A., Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry 2004, 161:826-835.
32. Oldham P.D. A note on the analysis of repeated measurements of the same subjects. J. Chron. Dis. 1962, 15:969-977.
33. Parsey R.V., Kent J.M., Oquendo M.A., Richards M.C., Pratap M., Cooper T.B., Arango V., Mann J.J. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol. Psychiatry 2006, 59:821-828.
34. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., Kerwin R.W. Limbic selectivity of clozapine. Lancet 1997, 350:490-491.
35. Ramamoorthy S., Blakely R.D. Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 1999, 285:763-766.
36. Savli M., Bauer A., Mitterhauser M., Ding Y.-S., Hahn A., Kroll T., Neumeister A., Haeusler D., Ungersboeck J., Henry S., Isfahani S.A., Rattay F., Wadsak W., Kasper S., Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage 2012, 63:447-459.
37. Scheperjans F., Grefkes C., Palomero-Gallagher N., Schleicher A., Zilles K. Subdivisions of human parietal area 5 revealed by quantitative receptor autoradiography: a parietal region between motor, somatosensory, and cingulate cortical areas. Neuroimage 2005, 25:975-992.
38. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47:27-38.
39. Smith G.S., Kahn A., Sacher J., Rusjan P., van Eimeren T., Flint A., Wilson A.A. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am. J. Geriatr. Psychiatry 2011, 19:1016-1025.
40. Stein P., Savli M., Wadsak W., Mitterhauser M., Fink M., Spindelegger C., Mien L.-K., Moser U., Dudczak R., Kletter K., Kasper S., Lanzenberger R. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2159-2168.
41. Steiner J.A., Carneiro A.M., Blakely R.D. Going with the flow: trafficking-dependent and -independent regulation of serotonin transport. Traffic 2008, 9:1393-1402.
42. 11C]FLB457. Psychopharmacology (Berl) 2012, 222:165-172.
43. Talbot P.S., Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur. Neuropsychopharmacol. 2002, 12:503-511.
44. Tu Y.K., Gilthorpe M.S. Revisiting the relation between change and initial value: a review and evaluation. Stat. Med. 2007, 26:443-457.
45. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002, 15:273-289.
46. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., Miller K.J., Spedding M., Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320:1-13.
47. Vauquelin G., Charlton S.J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 2010, 161:488-508.
48. Vernaleken I., Fellows C., Janouschek H., Brocheler A., Veselinovic T., Landvogt C., Boy C., Buchholz H.G., Spreckelmeyer K., Bartenstein P., Cumming P., Hiemke C., Rosch F., Schafer W., Wong D.F., Grunder G. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J. Clin. Psychopharmacol. 2008, 28:608-617.
49. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., Maziere B., Paillere-Martinot M.L. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 2001, 21:207-214.
50. Zeng Z., Chen T.-B., Miller P.J., Dean D., Tang Y.S., Sur C., Williams D.L. The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites. Nucl. Med. Biol. 2006, 33:555-563.
51. Zilles K., Amunts K. Receptor mapping: architecture of the human cerebral cortex. Curr. Opin. Neurol. 2009, 22:331-339.